—

Virbac SA (VIRP.PA) — the peer cohort

As of 2026-11-19 — scores re-bake nightly. Cohort = shared Closelooknet index membership first, then sector. Diary readings, not advice.

Virbac SA ranks 7 of 9 in its cohort on the Closelooknet composite (50/100) — the cohort is led by Eli Lilly and Company at 64/100.

NameCompositeMomentumQualityValuationSignalOff 52w high
VIRP.PA Virbac SA 50 61 52 56 info 11.3%
LLY Eli Lilly and Company 64 86 90 22 watch 6.3%
SAN.PA Sanofi SA 64 76 69 62 bull 3.1%
ORNAV.HE Orion Oyj A 63 95 84 28 ok 2.5%
ORNBV.HE Orion Oyj B 63 94 84 28 ok 3.2%
NVO Novo Nordisk A/S 56 30 86 72 bear 36.3%
AZN.L AstraZeneca PLC 55 59 75 45 info 14%
EL.PA EssilorLuxottica S. A. 47 47 47 48 bull 42.8%
ABVX.PA Abivax SA 38 18 53 56 warn 45.3%

Scores are relative readings across the Closelooknet coverage universe — methodology in the company-scoring explainer. Signal lights come from the nightly signal board.

FAQ · from the current data · as of 2026-11-19

Quick answers

Who are Virbac SA's peers in the Closelooknet universe?

The cohort is drawn from shared Closelooknet index membership first, then sector: Eli Lilly and Company (LLY), Sanofi SA (SAN.PA), Orion Oyj A (ORNAV.HE), Orion Oyj B (ORNBV.HE), Novo Nordisk A/S (NVO), AstraZeneca PLC (AZN.L), EssilorLuxottica S. A. (EL.PA), Abivax SA (ABVX.PA), as of 2026-11-19.

How does VIRP.PA score against its peers?

Virbac SA's composite reads 50/100, ranking 7 of 9 in its cohort as of 2026-11-19; the cohort's highest composite is Eli Lilly and Company at 64/100. Closelooknet scores are research diary readings, not ratings or advice.

Related in the Closelooknet universe

then Drug Manufacturers - General, then Healthcare. Scored names rank on their Closelooknet score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.